Compare Noble Corporation plc (NE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs TransMedics Group Inc — how do they compare? Noble Corporation plc trades at $42.45 (market cap $6.73B), while TransMedics Group Inc trades at $77.34 (market cap $2.74B). The key difference: Noble Corporation plc is far larger — about 2.5× TransMedics Group Inc's market cap, and Noble Corporation plc pays a 4.74% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and TransMedics Group Inc for 24 Days on average.
| NE | TMDX | |
|---|---|---|
Market Cap | $6.73B | $2.74B |
Volume | 1,027,635 | 949,331 |
Sector | Energy | Health |
52-Week High | $54.37 | $150.42 |
52-Week Low | $26.70 | $61.99 |
Typical Hold Time | 26 Days | 24 Days |
Enterprise Value | $8.16B | $3.13B |
Dividend Yield | 4.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.21, up 3.03% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income dropping from $217M to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though earnings have been inconsistent with two misses and one beat in the last four quarters.
The stock presents a cautious opportunity with analyst consensus target of $52.00 offering 23% upside, but faces headwinds from declining profitability and ongoing SEC investigation. Investors should weigh the contract wins against execution risks and margin pressure in the offshore drilling sector.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
